Humacyte, Inc. (Nasdaq: HUMA) is pioneering the development and manufacture of off-the-shelf, universally implantable bioengineered human tissues. The Humacyte Human Acellular Vessel (HAV) is a regenerative vascular conduit currently in various stages of clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. We believe our platform technology also has the potential to create solutions for complex organ disease, including bioengineered replacement tissues and organs for coronary artery bypass grafts, pediatric heart surgery, and the treatment of Type 1 diabetes.